C12N 2760/18422
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18422 (New viral proteins or individual genes, new structural or functional aspects of) appears on 137 US grants and 168 published applications in this corpus.
Search patents in C12N- Granted patents
- 137
- Published applications
- 168
- Assignees
- 125
- Inventors
- 313
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 8 | 0 |
| 1999 | 1 | 0 |
| 2000 | 11 | 0 |
| 2001 | 7 | 1 |
| 2002 | 2 | 4 |
| 2003 | 6 | 6 |
| 2004 | 6 | 5 |
| 2005 | 3 | 7 |
| 2006 | 4 | 8 |
| 2007 | 3 | 6 |
| 2008 | 5 | 6 |
| 2009 | 5 | 2 |
| 2010 | 4 | 7 |
| 2011 | 4 | 6 |
| 2012 | 2 | 4 |
| 2013 | 2 | 7 |
| 2014 | 1 | 4 |
| 2015 | 7 | 4 |
| 2016 | 3 | 4 |
| 2017 | 3 | 5 |
| 2018 | 4 | 6 |
| 2019 | 4 | 2 |
| 2020 | 5 | 5 |
| 2021 | 3 | 11 |
| 2022 | 4 | 8 |
| 2023 | 4 | 13 |
| 2024 | 5 | 17 |
| 2025 | 5 | 10 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant neuraminidase and uses thereof16 Jun 2026US 12,655,408 B2Icahn School of Medicine at Mount Sinai
- Targeted antigen delivery system and uses thereof26 May 2026US 12,636,378 B2SRI International
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Mutant KLF protein, and method for producing induced pluripotent stem cells24 Feb 2026US 12,559,730 B2Riken
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Expression construct10 Sep 2026US 2026/0265777 A1Lentitek Ltd
- Recombinant retrovirus, compositions, and methods of use30 Jul 2026US 2026/0218136 A1Kelonia Therapeutics, Inc.
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Synthetic peptide inhibitors of HIV transmission102US 5,464,933 ADuke University · 1995
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines76US 5,759,551 AUnited Biomedical, Inc. · 1998